Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Annexa

- PMLiVE

Boehringer plans €500m biopharma expansion in Austria

New production facility in Vienna will create 400 jobs when it comes online in 2021

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

- PMLiVE

BMS’ Empliciti approved by FDA for multiple myeloma

Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone

Bristol-Myers Squibb (BMS) building

Bump in the road slows momentum for BMS’ Opdivo

FDAturns down the cancer treatment for a form of melanoma

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

Bristol-Myers Squibb (BMS) building

Opdivo a breakthrough in kidney cancer, says FDA

BMSmoves closer to US approval of its checkpoint inhibitor cancer immunotherapy

- PMLiVE

FDA clears Jardiance combo for type 2 diabetes

Combination treatment Synjardy is fifth drug to come from Boehringer/Lilly diabetes alliance

Eli Lilly HQ

Lilly and Boehringer launch Lantus biosimilar in UK

Competition in the insulin drug market begins to heat up

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links